ATE250416T1 - Verfahren zur behandlung und vorbeugung von neurodegenerativen erkrankungen durch verabreichung von einem thiazolidin - Google Patents

Verfahren zur behandlung und vorbeugung von neurodegenerativen erkrankungen durch verabreichung von einem thiazolidin

Info

Publication number
ATE250416T1
ATE250416T1 AT97933264T AT97933264T ATE250416T1 AT E250416 T1 ATE250416 T1 AT E250416T1 AT 97933264 T AT97933264 T AT 97933264T AT 97933264 T AT97933264 T AT 97933264T AT E250416 T1 ATE250416 T1 AT E250416T1
Authority
AT
Austria
Prior art keywords
pct
thiazolidine
administration
treating
neurodegenerative diseases
Prior art date
Application number
AT97933264T
Other languages
English (en)
Inventor
Richard Thomas Carroll
Richard Dennis Dyer
Lillian Jane Robichaud
Brenda De Rae Shivers
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE250416T1 publication Critical patent/ATE250416T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
AT97933264T 1996-07-11 1997-07-01 Verfahren zur behandlung und vorbeugung von neurodegenerativen erkrankungen durch verabreichung von einem thiazolidin ATE250416T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2157196P 1996-07-11 1996-07-11
PCT/US1997/011586 WO1998002160A1 (en) 1996-07-11 1997-07-01 Method for treating and preventing neurodegenerative disorders by administering a thiazolidinone

Publications (1)

Publication Number Publication Date
ATE250416T1 true ATE250416T1 (de) 2003-10-15

Family

ID=21804973

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97933264T ATE250416T1 (de) 1996-07-11 1997-07-01 Verfahren zur behandlung und vorbeugung von neurodegenerativen erkrankungen durch verabreichung von einem thiazolidin

Country Status (23)

Country Link
US (1) US5912259A (de)
EP (1) EP0914122B1 (de)
JP (1) JP2001508028A (de)
KR (1) KR20000023683A (de)
CN (1) CN1145481C (de)
AT (1) ATE250416T1 (de)
AU (1) AU726664B2 (de)
BR (1) BR9710467A (de)
CA (1) CA2255073A1 (de)
CO (1) CO4940509A1 (de)
DE (1) DE69725147T2 (de)
DK (1) DK0914122T3 (de)
ES (1) ES2205247T3 (de)
HK (1) HK1020533A1 (de)
HR (1) HRP970362A2 (de)
IL (1) IL127487A (de)
NO (1) NO990076L (de)
NZ (1) NZ332763A (de)
PL (1) PL331049A1 (de)
PT (1) PT914122E (de)
TR (1) TR199900040T2 (de)
WO (1) WO1998002160A1 (de)
ZA (1) ZA976142B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003247514A1 (en) * 2002-06-11 2003-12-22 Roy Ogle Meningeal-derived stem cells
US20110104296A1 (en) * 2008-05-08 2011-05-05 Dipak Kumar Sarkar Endorphin Therapy Compositions and Methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL79648A (en) * 1985-08-09 1991-12-12 Lilly Co Eli Pharmaceutical anti-inflammatory and ischemia preventing compositions containing di-t-butylphenol derivatives,some such novel compounds and process for their preparation
DK0391644T3 (da) * 1989-04-07 1996-07-15 Lilly Co Eli Arylsubstituerede rhodaninderivater
US5143928A (en) * 1990-03-27 1992-09-01 Warner-Lambert Company 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
US5192753A (en) * 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
EP0915090A1 (de) * 1992-09-10 1999-05-12 Eli Lilly And Company Thiazolidinone Derivate als hypoglykämisches Mittel und für die Behandlung der Alzheimer Krankheit
WO1996022772A1 (en) * 1995-01-23 1996-08-01 Eli Lilly And Company Method for treating multiple sclerosis
ES2247604T3 (es) * 1995-06-12 2006-03-01 G.D. SEARLE & CO. Composiciones que comprenden un inhibidor de ciclooxigenasa-2 y un inhibidor de 5-lipoxigenasa.

Also Published As

Publication number Publication date
KR20000023683A (ko) 2000-04-25
PL331049A1 (en) 1999-06-21
US5912259A (en) 1999-06-15
NZ332763A (en) 2000-07-28
CN1223582A (zh) 1999-07-21
CO4940509A1 (es) 2000-07-24
PT914122E (pt) 2003-12-31
JP2001508028A (ja) 2001-06-19
AU726664B2 (en) 2000-11-16
CN1145481C (zh) 2004-04-14
NO990076D0 (no) 1999-01-08
NO990076L (no) 1999-01-08
AU3649197A (en) 1998-02-09
HK1020533A1 (en) 2000-05-12
IL127487A (en) 2002-04-21
DE69725147T2 (de) 2004-07-22
ZA976142B (en) 1998-02-02
CA2255073A1 (en) 1998-01-22
ES2205247T3 (es) 2004-05-01
TR199900040T2 (xx) 1999-04-21
DK0914122T3 (da) 2003-12-22
IL127487A0 (en) 1999-10-28
EP0914122A1 (de) 1999-05-12
EP0914122B1 (de) 2003-09-24
DE69725147D1 (de) 2003-10-30
WO1998002160A1 (en) 1998-01-22
BR9710467A (pt) 1999-08-17
HRP970362A2 (en) 1998-04-30

Similar Documents

Publication Publication Date Title
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
BG104686A (en) Glycine transport inhibitors
ATE207352T1 (de) Nicht-allosterische gaba a agonisten zur behandlung von schlafstörungen
DE69835823D1 (de) Verfahren zur behandlung von patienten die unter multipler sklerose leiden mit konsensus-interferon
ATE258067T1 (de) Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda- antagonisten enthält
ATE110958T1 (de) Verwendung von sertralin zur behandlung verfrühter ejakulation.
ATE181235T1 (de) Pharmazeutische zusammensetzungen und verfahren unter verwendung von isobutyramid zur behandlung von betaglobinerkrankungen
ATE390130T1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
WO1999048489A3 (en) Melatonin for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
DE69423577D1 (de) Verwendung von Oenothein B zur Herstellung eines Medikaments zur Behandlung der durch Hyperandrogenität bedingte Störungen.
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE250416T1 (de) Verfahren zur behandlung und vorbeugung von neurodegenerativen erkrankungen durch verabreichung von einem thiazolidin
ATE294582T1 (de) Verwendung von alpha-1-adrenorezeptor- antagonisten zur herstellung eines medikaments für die vorbeugung und die behandlung von krebs
DE69533311D1 (de) Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen
ATE216237T1 (de) Verwendung von ropivacaine zur herstellung eines analgetikums mit minimaler motorischer blockade
DE69626916D1 (de) Sertralin zur Behandlung von Post-Myocard-Infarkt-Patienten
ATE271881T1 (de) Verwendung von hyaluronidase zur prophylaxe und behandlung von herz-kreislauf-erkrankungen
ATE194076T1 (de) Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen
ATE215368T1 (de) Verwendung von forskolin oder diese enthaltende extrakte zur herstellung eines medikaments für die behandlung von alkoholsucht
DE69421705D1 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
DE69632117D1 (de) Verwendung von 8,9-Dehydroestron zur Herstellung eines Arzneimittels zur Behandlung von durch freie Radikale verursachte Krankheiten
DE69928814D1 (de) Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten
DE69909970D1 (de) Verwendung von 2-amino-6-trifluoromethoxybenzothiazol zur herstellung eines arzneimittels zur vorbeugung oder behandlung von zerebellumkrankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0914122

Country of ref document: EP

REN Ceased due to non-payment of the annual fee